Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia

Growth Factors

Volumn 27, Issue 2, 2009, Pages 71-78

  Stachon, Axel ^a   Aweimer, Assem ^a   Stachon, Tanja ^a   Tannapfel, Andrea ^a   Thoms, Sven ^b   Ubrig, Burkhard ^c   Köller, Manfred ^a   Krieg, Michael ^a   Truss, Michael C ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c KLINIKUM DORTMUND   (Germany)

Author keywords

Microvascular endothelial cells; Prostate; TNF ; VEGF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; RECOMBINANT PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CELL CULTURE; CELL FRACTIONATION; CELL ISOLATION; CELL STIMULATION; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FAST PROTEIN LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN SECRETION; RECEPTOR BINDING; REGULATORY MECHANISM; VASCULAR ENDOTHELIUM; CELL LINE; DRUG EFFECT; MALE; METABOLISM; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PATHOLOGY; PROSTATE; VASCULARIZATION;

CELL LINE; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; HUMANS; MALE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; PROSTATE; PROSTATIC HYPERPLASIA; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 66949162989     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190802709619     Document Type: Article

References (41)

1. Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U, Esser N, MarmeD. 2005. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 30:249-257.
2. Bates M, Kovalenko B, Wilson L, Moscatelli D. 2008. Endothelial cells support the growth of prostate tissue in vivo. Prostate 68: 893-901.
3. Campbell CL, Savarese DM, Quesenberry PJ, Savarese TM. 1999. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor. Int J Cancer 80:868-874.
4. Cebe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. 2006. The role of VEGF receptors in angiogenesis; complex partnership. Cell Mol Life Sci 63:601-615.
5. Dall'Era MA, Shih SJ, Yang J, Benik S, Gandour-Edwards R, Evans CP. 2001. Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer. Prostate Cancer Prostatic Dis 4:106-111.
6. Ebos JML, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS. 2004. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2:315-326.
7. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. 2008. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68:521-529.
8. Folkman J. 1998. Editorial: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139:441-442.
9. Franck-Lissbrandt I, Häggström S, Damber J-E, Bergh A. 1998. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139: 451-456.
10. Gerritsen ME. 1987. Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol 36:2701-2711.
11. Gimbrone Jr. MA, Cotran RS, Folkman J. 1974. Human vascular endothelial cells in culture. J Cell Biol 60:673-684.
12. Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB. 2000. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 275:11216-11221.
13. Häggström S, Bergh A, Damber J-E. 2000. Vascular endothelial growth factor content in metastasizing and nonmetastasizing dunning prostatic adenocarcinoma. Prostate 45:42-50.
14. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. 2000. Expresssion of the VEGF-receptor flt-1 in benign, premalignant and malignant prostate tissues. J Urol 164:506-510.
15. Hrouda D, Nicol DL, Gardiner RA. 2003. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 30:347-355.
16. Janßen M, Albrecht M, Möschler O, Renneberg H, Fritz B, Aumüller G, Konrad L. 2000. Cell lineage characteristics of human prostatic stromal cells cultured in vitro. Prostate 43: 20-30.
17. Joseph IB, Isaacs JT. 1998. Macrophage role in the anti-prostate cancer response to one class of angiogenic agents. J Natl Cancer Inst 90:1648-1653.
18. Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, Patterson C, Annex BH, Bautch VL. 2008. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 181:847-858.
19. Krupski T, Harding MA, Herce ME, Gulding KM, Stoler MH, Theodorescu D. 2001. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 18:287-302.
20. Latil A, Bieche I, Pesche S, Valeri A, Fournier G, Cussenot O, Lidereau R. 2000. VEGF overexpression in clinically localized prostate tumors and neuropillin-1 overexpression in metastatic forms. Int J Cancer 89:167-171.
21. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. 2001. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35:437-452.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
23. Nakagami H, Cui TX, Iwai M, Shiuchi T, Takeda-Matsubara Y,Wu L, Horiuchi M. 2002. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol 22:238-242.
24. Nakajima Y, DelliPizzi A, Mallouh C, Ferreri NR. 1995. Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines. Urol Res 23: 205-210.
25. Pieh C, Agostini H, Buschbeck C, Kruger M, Schulte-Monting J, Zirrgiebel U, Drevs J, Lagreze WA. 2008. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: Relationship to retinopathy of prematurity. Br J Ophthalmol 92: 689-693.
26. Polnaszek N, Kwabi-Addo B,Wang J, Ittmann M. 2004. Fgf17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia. Prostate 60:18-24.
27. Pradeep CR, Sunila ES, Kuttan G. 2005. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 4:315-321.
28. RoecklW, Hecht D, Sztajer H,Waltenberger J, Yayon A,Weich HA. 1998. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 241:161-170.
29. Shibuya M. 2003. Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E. Cancer Sci 94: 751-756.
30. Shibuya M. 2006a. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469-478.
31. Shibuya M. 2006b. Vascular endothelial growth factor (VEGF)-Receptor2: Its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13:63-69.
32. Sordello S, Bertrand N, Plouet J. 1998. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251:287-290.
33. Stachon A, Schlüter T, Köller M, Weisser H, Krieg M. 2001. Primary culture of microvascular endothelial cells from human benign prostatic hyperplasia. Prostate 48:156-164.
34. Stachon A, Schlüter T, Junker K, Knopf HJ, Neuser RD, Krieg M. 2004. The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor. Growth Factors 22: 281-289.
35. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. 1994. Macrophages and angiogenesis. J Leukoc Biol 55: 410-422.
36. Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J, Mulligan RC, Carter BS. 2008. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: Laboratory investigation. J Neurosurg 108:979-988.
37. Thorin E, Shatos MA, Shreeve SM, Walters CL, Bevan JA. 1997. Human vascular endothelium heterogeneity. A comparative study of cerebral and peripheral cultured vascular endothelial cells. Stroke 28:375-381.
38. van Moorselaar RJ, van Stratum P, Borm G, Debruyne FM, Schalken JA. 1991. Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate 18:331-344.
39. Vogel C, Bauer A, Wiesnet M, Preissner KT, SchaperW, Marti HH, Fischer S. 2007. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. J Cell Physiol 212: 236-243.
40. Wierzbowska A, Robak T, Wrzesien-Kus A, Krawczynska A, Lech-Maranda E, Urbanska-Rys H. 2003. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 14:149-153.
41. Zhao X, van Steenbrugge GJ, Schroder FH. 1992. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urol Res 20:193-197.